Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding Issue of duplicate share certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 09,2020 for Pronomz Ventures LLP, Karuna Business Solutions LLP & Arunkumar Pillai Strides Pharma stock gains over 5% on USFDA nod for generic ointment
Following the update, Strides Pharma Science stock touched an intraday high of Rs 421, rising 5.36% against the last closing value of Rs 399.60 on BSE Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Triamcinolone Acetonide Ointment
Buy Strides Pharma Science; target of Rs 421: ICICI Securities
ICICI Securities is bullish on Strides Pharma Science has recommended buy rating on the stock with a target price of Rs 421 in its research report dated May 21, 2020. Strides Pharma Science Ltd - 532531 - Clarification / Confirmation On News Item Appearing In 'Media/Publication'
Clarification / Confirmation on news item appearing in 'Media/Publication' Strides Pharma Science Ltd - 532531 - Clarification sought from Strides Pharma Science Ltd
The Exchange has sought clarification from Strides Pharma Science Ltd with respect to news article appearing on economictimes.indiatimes.com May 21, 2020 titled "Strides Pharma to conduct trials in India for potential COVID-19 drug".The reply is awaited.
Earnings Call Transcript - Q4FY20 for Strides Pharma Science
Conference Call with Strides Pharma Science Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen in to the full transcript. Management Comments Arun Kumar, Chairman I ended my watch as executive MD of the company on 31st March. It's been a strong year of performance. We are pretty proud of what we achieved. Two very important elements of the year: significant uptick in the gross margins with reported increasing over 10%. Two consecutive quarters where our gross margins exceeded 60%. We think this is a phenomenal shift in product selection and execution. We guided in the beginning at $240-250 million for the FY. We are at the high end of the range. We haven't lost market share or dropped price on any products in the last six quarters. Ranitidine was withdrawn by the FDA across companies after working hours in 31st of March. Overall we grew the business 5X from $50 to $240 million. Ranitidine: The work FDA has asked us to do will take several quarters. We don't believe this molecule will go back into the market for at least two years. We believe the work is worth it. After its launch in November, we were seeing annualized run rate of $75 million on the product. This would have sped up our achieving our targets faster. Regarding filings, we have reached a plateau for where we need to get to the $400 million run rate, we don't envision any significant new filings immediately. Institutional business has been tepid, but we have focused on profitable products. Several financial outcomes have been achieved this year. Hardly any expansion of the debt book. (In response to a question) says that pledges on his promoter shares will go to zero. Komandur Badree, CFO FY20 has witnessed strong execution and balance sheet. Sustainable EBITDA margins, profitability, efficiency our focus. Solid operating leverage which led to EBITDA margin expansion of 740 bps excepting Ranitidine. Reporting strong operating cash flow of 2,500 million rupees. Completed our capex programs. Our debt levels are comfortable. Ratio of 1.9 (debt/ebitda). ROCE % is up. Reduced our contingent liabilities by 13 billion rupees. Focus on generating free cash and improving return ratios. Dr. R Ananthanarayanan, CEO and MD We have achieved significant milestones this year. Not withstanding disruptions in manufacturing due to lockdowns, we didn't see significant impact from COVID19. There has been some depletions of inventory but otherwise we have stayed resilient. Even though uncertainty exists in the COVID19 outbreak, we believe we are well positioned. US business: we are confident in our future performance in the US markets. We expect growth of 25-30% even without Ranitidine going forward. We launched six products in Q3FY20 delivering annualized revenues of $45 million. We have a basket of 35 products that are approved but not commercialized. We are looking at launching at least five of these products. Improvements in gross margins consistently in two quarters. Strides Pharma To Conduct Trials For Potential COVID-19 Drug
Bengaluru-based Strides Pharma Science has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country. Strides Pharma Science Ltd - 532531 - Board recommends Final Dividend
Strides Pharma Science Ltd has informed BSE that Board of Directors at their meeting held on May 20, 2020, have recommended Final Dividend of at Rs. 2/- per equity share of Rs. 10/- each for the financial year ended March 31, 2020. The dividend will be paid within 30 days from the date of shareholder's approval at the ensuing Annual General Meeting of the Company.After taking into account the interim dividend of Rs. 12/- per share paid by the Company in the month of August 2019, total dividend for the financial year stands at Rs. 14/- per equity share.